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Scorpion venom heat-resistant peptide (SVHRP) is a component purified from Buthus
martensii Karsch scorpion venom. Our previous studies found SVHRP could enhance
neurogenesis and inhibit microglia-mediated neuroinflammation in vivo. Here, we use
the transgenic CL4176, CL2006, and CL2355 strains of Caenorhabditis elegans which
express the human Aβ1 42 to investigate the effects and the possible mechanisms−
of SVHRP mediated protection against Aβ toxicity in vivo. The results showed that
SVHRP-fed worms displayed remarkably decreased paralysis, less abundant toxic Aβ
oligomers, reduced Aβ plaque deposition with respect to untreated animals. SVHRP
also suppressed neuronal Aβ expression-induced defects in chemotaxis behavior and
attenuated levels of ROS in the transgenic C. elegans. Taken together, these results
suggest SVHRP could protect against Aβ-induced toxicity in C. elegans. Further studies
need to be conducted in murine models and humans to analyze the effectiveness of the
peptide.
Keywords: scorpion venom heat-resistant peptide, C. elegans, alzheimer’s disease, amyloid beta-peptide,
behavior
INTRODUCTION
Alzheimer’s disease (AD) is the most common progressive neurodegenerative disease (Goedert
and Spillantini, 2006), affecting a large proportion of elderly individuals in the world (Sloane et al.,
2002). More recently, numerous studies have suggested that soluble, small oligomeric forms of
amyloid beta-peptide (Aβ) are the main toxic species to neurons (Kayed et al., 2003; Nimmrich
and Ebert, 2009; Taylor et al., 2010). Accordingly, the focus of the research into molecules able
to delay AD occurrence and to relieve its symptoms has shifted from hindering fibril growth to
avoiding the appearance of toxic oligomeric intermediates.
Transgenic Caenorhabditis elegans (C. elegans) which express the human Aβ1−42 offer an
original in vivo model for investigating the toxicity specifically related to small oligomeric Aβ
(Link, 1995). Transgenic C. elegans strain, CL4176, expressing human Aβ1−42 in muscle cells
under a temperature-inducible system (Link et al., 2003), become rapidly paralyzed. Another
C. elegans strain, CL2006, which constitutively expresses human Aβ1−42 in body wall muscle
tissues (Link, 1995, 2005), displays an age-related progressive reduction of muscle specific motility
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which is related to the accumulation of both Aβ1−42 fibrils and
oligomers. Two characteristic neuronal controlled behaviors, 5-
HT sensitivity and chemotaxis, are defects in CL2355 which
has inducible neuronal Aβ expression (Wu et al., 2006). All
of these strains have already been used to screen for drugs
aimed to ameliorate Aβ toxicity such as Gingko biloba extract
EGb 761(Wu et al., 2006), green tea component epigallocatechin
gallate (Abbas and Wink, 2010) and other compounds (McColl
et al., 2009; Morita et al., 2009; Dostal et al., 2010; Yu et al., 2010;
Martorell et al., 2013).
Many natural product-based therapies have been used to
prevent or treat age-related deterioration in cognitive or memory
function (Howes and Houghton, 2003; Jiang et al., 2003; Yan et al.,
2007). Buthus martensii Karsch (BmK) and its venom have been
used as drugs for treating nervous system diseases in traditional
Chinese medicine, such as epilepsy and cerebral infarction (Wang
et al., 2009) for thousands of years. Obviously, at first glance, it
may seem odd to consider scorpion toxins as potential drugs.
However, scorpion venoms are a complex mixture of about 100
to 1000 different components. Typically, low molecular mass
(<3 kDa) peptides derived from scorpion venoms are highly
diverse in both their primary structures and biological activities
and this renders them potentially intriguing therapeutic agents
to explore (Keramidas et al., 2004; Zeng et al., 2005; Elgar et al.,
2006).
Our laboratory isolated one scorpion venom heat-resistant
peptide (SVHRP) from BmK venom (Wang et al., 2014; Yin
et al., 2014; Cao et al., 2015). Our previous studies showed
that this peptide had neurotrophic and neuroprotective effects
(Yin et al., 2014). More recently, it was observed that SVHRP
could enhance neurogenesis and stimulate neural maturation
by up-regulating Brain Derived Neurotrophic Factor (BDNF)
both in vivo and in vitro (Wang et al., 2014). In addition,
previous studies have observed that Buthus martensi Karsch
extracts exert anti-inflammatory effects related to the inhibition
of neutrophil functions and of NO and PGE2 production
through the transcription factors NF-(kappa) B and AP-1(Kim
et al., 2005). Neuronal death is considered as main cause of
dementias and neuroinflammation play an important role in the
progression of AD (Calsolaro and Edison, 2016). Taken together,
these results suggest us SVHRP may be effective in AD therapy.
In this study, we used transgenic C. elegans that exhibit several
pathological behaviors induced by Aβ toxicity as a simplified
invertebrate model of AD (Link, 1995, 2005), to evaluate the
protective effects of SVHRP against Aβ toxicity in vivo and
elucidate some of the mechanisms involved in protective effects
of SVHRP in C. elegans.
MATERIALS AND METHODS
Isolation of Scorpion Venom
Heat-Resistant Peptide
The isolation of SVHRP from BmK venom has been reported
in our previously published paper (Cao et al., 2015). All drugs
for treatment of experimental animals were added directly to the
food.
Caenorhabditis elegans Strain
The wild-type C. elegans strain N2, the transgenic strain CL2006,
the transgenic strain CL2355 and the control strain CL2122,
transgenic strain CL4176 and the control CL802 strain were
used. The CL2006 strain constitutively expresses Aβ1−42 in
the cytoplasm of body wall muscle cells, while the transgenic
CL4176 worms express muscle-specific Aβ1−42 by raising the
temperature from 16 to 23◦C. The CL2355 strain expresses
Aβ1−42 in the neuronal cells and the expression of neuron-
specific Aβ1−42 depends on temperature upshift. All of the
C. elegans strains were purchased from Caenorhabditis Genetic
Center (University of Minnesota, USA).
C. elegans Maintenance and Treatment
The transgenic CL2006 and the wild-type (N2) were propagated
at 20◦C, while CL2355, CL4176, and their controls were
maintained at 16◦C. All C. elegans strains were routinely
propagated on solid nematode growth medium (NGM) with
100 µl spots of OP50 (Escherichia coli strain) as a food source.
To prepare age-synchronized nematodes, worms were allowed to
lay eggs for 4–6 h (overnight for Western blotting of CL2006 and
CL4176). Then, isolated the adult worms from the synchronized
eggs (day 1) and the synchronized eggs were cultured on fresh
NGM plates (containing vehicle or SVHRP) in either 20◦C or
a 16◦C (for CL4176, CL2355, and their control strains). In the
experiments, the worms were fed with the drugs from the egg
through to adult stages and transferred to new plates (containing
different concentrations of drugs) every day.
Paralysis Asssays
Synchronized eggs of CL802 and CL4176 were maintained
at 16◦C, on the NGM plates containing vehicle or different
concentrations of drugs. Transgene expression was induced by
upshifting the temperature from 16 to 23◦C, started at the 36th
hour after egg laying and lasted until the end of the paralysis
assay. The scoring was performed at an hourly interval typically
after 24 h at 23◦C until the last worm became paralyzed. The
worms that did not move or only moved their head when gently
touched with a platinum loop were scored as paralyzed. Each
experiment was performed using at least 100 worms.
Western Blotting of Aβ Species
The Aβ species in the transgenic C. elegans strains was identified
by immunoblotting using a Tris-Tricine gel and the standard
Western blotting protocol except that the polyvinylidene
difluoride membranes were boiled for 5 min after the transfer.
After the experimental treatments, the worms were collected,
washed with M9 buffer, flash frozen in liquid nitrogen,
sonicated in the lysis buffer (62 mM Tris-HCl pH 6.8, 5%
β-mercaptoethanol (v/v), 10% glycerol (v/v), 2% SDS (w/v), and
1X protease inhibitor cocktail), and heated with sample buffer
containing 5% β-mercaptoethanol. After heating with the sample
buffer, the proteins were cooled and equal amounts of the total
protein (60−80 µg) were loaded in each lane. Amyloid protein
species were detected with 6E10 monoclonal antibody (1:750,
Covance); secondary anti-mouse IgG peroxidase conjugate
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(1:5000; Sigma). Tubulin was detected with anti-tubulin antibody
(1:2000, Abcam). The mean densities of β-amyloid reactive bands
were analyzed by ImageJ (National Institutes of Health, USA).
Fluorescent Staining of β-Amyloid with
Thioflavin-S
Age-synchronized transgenic CL2006 worms fed or not fed
with SVRHP were incubated at 20◦C and at 120 h of age the
worms were fixed overnight in 4% paraformaldehyde/phosphate-
buffered saline (PBS), pH 7.4, at 4◦C. Then the nematodes were
permeabilized in 1% Triton X-100, 5% fresh β-mercaptoethanol,
125 mM Tris, pH 7.4, in a 37◦C incubator for another 24 h.
The worms were stained with 0.125% thioflavin S (Sigma)
in 50% ethanol for 2 min. The samples were then destained
with sequential washes with ethanol, mounted on slides for
microscopy and observed with a microscope (DM4000B; Leica,
Germany) equipped with a digital camera. Fluorescence images
were acquired using a CDD. The number of thioflavin S positive
spots in the head region of worms fed with vehicle (n = 72)
or SVHRP (n = 72) were scored. The data expressed as Aβ
deposits/anterior area.
Measurement of Reactive Oxygen
Species (ROS) in C. elegans
Intracellular ROS was measured in C. elegans using 2, 7-
dichlorofluorescein diacetate (H2DCF-DA) as described
previously (Kampkotter et al., 2007). Briefly, age-synchronized
C. elegans (50 eggs per plate) were transferred to NGM plates
containing vehicle or different concentrations of SVHRP (2, 20,
40 µg/ml) and incubated for 36 h at 16◦C. The worms were
collected into a microfuge tube at 36 h after temperature upshift,
washed twice with PBS to remove E. coli (OP50) and transferred
into the wells of 96-well plate containing 200 µl of PBS, 0.01%
Tween-20 and 50 Mm H2DCF-DA (final concentration in PBS).
The fluorescence was quantified in a Synergy HT microplate
fluorescence reader (Bio-Tek Instruments, Winooski, VT, USA)
every 30 min for 2.5 h at 37◦C using the excitation at 485 nm and
emission at 530 nm. The fluorescent images of DCF were taken
with a FITC excitation and emission filter setup.
Chemotaxis Assays
Chemotaxis assays (see Figure 5A) were performed as described
by Olivia Margie (Margie et al., 2013). Synchronized transgenic
C. elegans CL2355 and its control strain CL2122 were treated with
or without SVHRP, starting from the egg. They were cultured in
16◦C for 36 h, and then in 23◦C for another 36 h. The worms
were then collected and assayed in 100 mm plates containing
25 mM phosphate buffer, pH 6.0, 1 mM MgSO4, 1 mM CaCl2,
and 1.9% agar. 1 µl of 0.25M sodium azide along with 1 µl of
odorant (0.1% benzaldehyde in 100% ethanol) were added to
the “attractant” spot. On the opposite side of the attractant spot,
1 µl of control odorant (100% ethanol) and 1 µl drop of sodium
azide were added. Immediately after, pipette 2 µl of the worms
(about 60 worms) to the center of the plate. Incubate the assay
plates at 23◦C for 1 h and then the number of worms in each
quadrant was scored. Calculate the Chemotaxis index (CI) using
Equation: CI= (number of worms in both attractant quadrants –
number of worms in both control quadrants)/total number of
scored worms.
Statistical Analyses
Statistical analysis was performed using GraphPad (Version 5.0
for Macintosh OSX, GraphPad Software, San Diego, CA, USA).
Significance was assessed by a one-way analysis of variance
(ANOVA), followed by Newman–Keuls’s Test, or Student’s t-test
of two groups. Values of p < 0.05 were considered statistically
significant.
RESULT
Aβ-Induced Paralysis is Alleviated by
SVHRP in Transgenic C. elegans
We first investigated whether SVHRP protect against Aβ-induced
toxicity in the transgenic C. elegans strain CL4176. Figure 1A
showed when the SVHRP were administered, the time at which
the temperature was raised in CL4176 and CL802 worms, and
when the paralysis assay was rated. The feeding of CL4176
worms with SVHRP (2, 80 µg/ml) starting at eggs did not
delay Aβ-induced paralysis but in the transgenic worms fed
with SVHRP (20, 40 µg/ml), a notable delay of paralysis was
observed compared with the vehicle-treated controls (Figure 1B).
For quantitative analysis, we define PT50 value, i.e., the time
interval, from the onset of paralysis, at which half the worms
were paralyzed. The PT50 was significantly higher in worms fed
the SVHRP (20, 40 µg/ml) compared to the control (Figure 1C,
5.3 ± 0.75 for vehicle-treated CL4176 worms and 8.0 ± 0.76,
10.0 ± 0.7 for nematodes fed 20, 40 µg/ml SVHRP). These
observations suggest that SVHRP may have the potential to
protect against Aβ-induced toxicity in the whole animal.
SVHRP Affects Aβ Oligomerization in
Transgenic C. elegans
Since the paralysis of CL4176 is caused by the Aβ toxicity,
naturally we wanted to examine if the effect of SVHRP on delayed
paralysis was associated with a decrease in Aβ accumulation in
transgenic CL4176. We analyzed Aβ species from the transgenic
C. elegans fed with or without SVHRP by Western blotting using
antibodies against Aβ (6E10). Another C. elegans strain, CL2006,
constitutively expressing cytoplasmic human Aβ1−42 in the body
wall muscle cells, was considered too. This strain displays an age-
related progressive reduction of muscle specific motility which is
related to the accumulation of both Aβ1−42 fibrils and oligomers.
Figure 2A shows Aβ-immunoreactive (6E10) bands detected in
the tissues from the transgenic worms (CL2006, CL4176, and
the control strain CL802) fed with or without SVHRP. The
visual observation of immunoblot showed a specific reduction
of Aβ oligomeric species, which are responsible for the toxicity
and initiation of synaptic dysfunction observed in AD (Lesne
et al., 2006; Oddo et al., 2006; Nimmrich and Ebert, 2009; Taylor
et al., 2010). The mean densities of the Aβ oligomer bands at
20 kDa were analyzed. Statistically, SVHRP significantly reduced
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FIGURE 1 | Scorpion venom heat-resistant peptide (SVHRP) delayed β-amyloid induced paralysis in transgenic Caenorhabditis elegans strain
CL4176. (A) Diagram illustrating the paralysis assays showing the time at which the temperature was raised in CL4176 and CL802 worms, when the paralysis assay
was scored and SVHRP protective effect at different treatment regimens. (B) Time course of Aβ-induced paralysis in the transgenic CL4176 strain treated with a
vehicle (Ctrl) or different concentrations of SVHRP (2−80 µg/ml). Data are shown as percentages ± SD of worms not paralyzed (n = 100, three independent
assays). (C) The paralysis assays were quantified for mean time duration at which 50% worms were paralyzed (PT50) from the transgenic worms fed with or without
SVHRP. Error bars indicate SD (n = 100, three independent assays, ∗p < 0.05, ∗∗p < 0.01 vs. control group).
the oligomers both in CL4176 and in CL2006 (Figures 2B,C;
n= 3; CL2006, Ctrl vs. SVHRP, p= 0.01; CL4176, Ctrl vs. SVHRP,
p= 0.013).
SVHRP Reduces Amyloid Deposition in
Transgenic C. elegans
Further, we scored the number of amyloid-reactive deposits
in the head of C. elegans strain CL2006 to evaluate whether
the inhibitory effect of SVHRP on Aβ oligomerization would
reduce the degree of amyloidosis. Figures 3b,c shows Aβ deposits
(white arrows) detected in CL2006 but not the wild type (N2)
(Figure 3a), as previously observed (Link, 1995). Figure 3d shows
that the mean number of Aβ deposits was significantly reduced
in worms fed with 40 µg/ml SVHRP. These results implied that
the protective effect of SVHRP against Aβ induced toxicity in the
worms, may be due to inhibit Aβ oligomerization and deposition.
SVHRP Inhibits Superoxide Production in
C. elegans
Oxidative stress occurs in transgenic C. elegans strains expressing
human Aβ1−42 and the increase of superoxide levels precedes
the paralysis (Gutierrez-Zepeda et al., 2005; Luo, 2006). Given
that a number of studies have associated oxidative stress with
Aβ toxicity and AD, we investigated the in vivo ROS activity
in transgenic strain, CL4176, to determine whether SVHRP
has effect in reducing ROS in transgenic C. elegans. Three
concentrations of SVHRP (2, 20, and 40µg/ml) were added to the
transgenic C. elegans from egg until the end of the temperature
upshift. Compared to the control strain CL802, ROS levels rose
significantly in Aβ expressing transgenic strains (Figure 4B).
As expected, feeding SVHRP attenuated the intracellular levels
of ROS in a dose-dependent manner (Figures 4A,B). Feeding
40 µg/ml SVHRP exhibited most significant reduction (Ctrl,
100 ± 16.5%; SVHRP, 41.4 ± 11.2%; n = 3; p = 0.007). These
results suggest that the delayed onset of Aβ related paralysis
phenotype in CL4176 worms with SVHRP treatment might be,
in part, due to the ROS suppressing properties of SVHRP.
SVHRP Suppresses Neuronal Aβ
Expression-Induced Defect in
Chemotaxis Behavior
Numerous studies have suggested that small oligomeric forms
of Aβ-peptide are the main toxic species to neurons. Next,
we used a transgenic strain, CL2355, which Aβ was expressed
in the neuronal cells, to investigate whether the inhibitory
effect of SVHRP on Aβ oligomerization would protect neuron
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FIGURE 2 | Scorpion venom heat-resistant peptide reduced β-amyloid oligomers in C. elegans. (A) Representative western blot of Aβ species in CL2006,
CL4176, and CL802 worms fed vehicle or SVHRP. CL2006 maintained at 20◦C fed with a vehicle (Ctrl), SVHRP (40 µg/ml) for 96 h. CL4176 and CL802 worms fed
with a vehicle (Ctrl), SVHRP (40 µg/ml) were maintained for 36 h at 16◦C, then the temperature was raised from 16 to 23◦C. 25 h later, the worms were collected
and equal amounts of protein were loaded in each lane and immunoblotted with anti-Aβ antibody (6E10) or tubulin. Arrows indicate the Aβ oligomers (20 kDa).
Quantification of Aβ oligomers (the band at 20 kDa) in CL2006 (B) and CL4176 (C) worms fed either vehicle or SVHRP using ImageJ software. Data are expressed
as mean density of the indicated band based from three independent experiments. Error bars represent SD. ∗p < 0.05.
FIGURE 3 | Aβ deposits in transgenic C. elegans CL2006 fed with or without SVHRP. Representative images of C. elegans with thioflavin S staining in the wild
type (a), or in the transgenic strain CL2006 fed with (c) or without SVHRP (b). The number of deposits (arrows) was scored in the worm head (d). Data were
obtained from three experiments with 24 worms in each group (n = 72). The quantity is expressed as mean number of β-amyloid deposits in the head region
/anterior area of the worm. Error bars indicate SE. ∗p < 0.05.
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FIGURE 4 | Effect of SVHRP on reactive oxygen species (ROS) production in transgenic C. elegans strains. Age-synchronized CL4176 or CL802 worms,
fed vehicle or different concentrations of SVHRP (2, 20, 40 µg/ml) were collected 36 h after the temperature rise followed by the DCF (2, 7-dichlorofluorescein
diacetate) assay for ROS described in Materials and Methods. (A) DCF fluorescent images of nematodes fed vehicle or different concentrations of SVHRP. Scale
bars: 100 µm. (B) The DCF fluorescence intensity was detected by a microplate reader at 485 nm excitation and 530 nm emission. Results are expressed as
percentage of fluorescence (%DCF) relative to vehicle-treated controls, which is set as 100%. Data were obtained from three experiments with 50 worms in each
experiment. Error bars indicate SE, ∗p < 0.05, ∗∗p < 0.01 vs. control group).
against Aβ-induced toxicity. The neuronal controlled behaviors,
chemotaxis, were assayed in these worms. The CI is a measure
of the fraction of worms that are able to arrive at the location
of the attractants (Adachi et al., 2008; Margie et al., 2013).
Figure 5B shows that the CI value was significantly reduced
in transgenic strain CL2355 compared to the control strain
CL2122 (Ctrl CICL2355, 0.21± 0.03 vs. Ctrl CICL2122, 0.46± 0.05;
n = 3; p < 0.001). SVHRP(40 µg/ml) feeding of the control
strain had no effect on their CI (Ctrl CICL2122, 0.46 ± 0.05, vs.
SVHRP CICL2122, 0.47 ± 0.06; n = 3; p = 0.78), but it obviously
normalized the reduced CI in neuronal Aβ transgenic strain in a
concentration-dependent manner (0.21 ± 0.03 for Ctrl CL2355
worms and 0.22 ± 0.03, 0.39 ± 0.06, 0.43 ± 0.04 for nematodes
fed 2, 20, 40 µg/ml SVHRP). These results suggest that SVHRP
might be able to protect neuro against Aβ-induced toxicity and
rescue neuronal Aβ expression-induced defects in chemotaxis
behavior.
DISCUSSION
Here, we first observe the effects of SVHRP-polypeptide extract
from scorpion venoms in Aβ transgenic C. elegans. By using
transgenic C. elegans, CL4176, we examined if SVHRP could
reduce paralysis resulting from Aβ1−42 peptide expression.
Our data showed a significant delay of Aβ induced paralysis
in SVHRP-treated (20, 40 µg/ml) worms (Figure 1B) and
the effects were dose-dependent. The lower dose of SVHRP
(2µg/ml) was too low to produce protective effects and the
higher doses (80 µg/ml) tended to be toxic, causing the death
of worms. A recent study evaluated the drug metabolism rate in
C. elegans (Zheng et al., 2013) and they found the metabolism
rate increased gradually with the passing of time and reached
the highest at the time interval of 8 to 12 h in C. elegans
(Zheng et al., 2013). In this study, feeding the CL4176 worms
with SVHRP before Aβ expression, or after Aβ expression by
temperature upshift could not delay the paralysis (data not
shown) (see diagram in Figure 1A) and similar results were
obtained in worms fed the EGb 761 (Wu et al., 2006) and
Oleuropein Aglycone (Diomede et al., 2013), suggesting that
short duration of feeding may not be sufficient to alleviate Aβ
toxicity.
Substantial studies implicate intracellular Aβ oligomers in
early events are related to AD (Kienlen-Campard et al.,
2002; Umeda et al., 2015) and responsible for the early
cognitive impairment observed in patients before the amyloid
plaque deposits appear (Kayed et al., 2003; Nimmrich and
Ebert, 2009; Taylor et al., 2010). Accordingly, inhibition of
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FIGURE 5 | Assays for chemotaxis behavior in neuronal Aβ-expressing strain CL2355. (A) Schematic diagram of the chemotaxis assay. Plates were divided
into quadrants two test (A&D) and two controls (B&C). Sodium azide was also included with the attractant and control odorant to paralyze worms. Worms were
placed at the center of the plate and after 60 min worms were counted on each quadrant. Schematic examples of neutral and attractant are indicated. (B) The
Chemotactic Index (CI) in the neuronal strain CL2355 and the transgenic control strain CL2122 fed with vehicle or different concentration of SVHRP (2, 20,
40 µg/ml). Data were obtained from three experiments with 60 worms in each group. Error bars indicate SD (∗∗p < 0.01 vs. CL2355 control group).
Aβ aggregation would be a potential therapeutic strategy.
Some oligomers (20 kDa) were inhibited by SVHRP as
observed in this study (Figure 2A). A similar effects have
previously been reported for a cocoa peptide (Martorell et al.,
2013) and glycitein from soybeans (Gutierrez-Zepeda et al.,
2005). Moreover, the inhibitory effects of SVHRP on Aβ
oligomerization would affect amyloid deposition. The analysis of
fibrillar deposits in adult CL2006 worms showed a significantly
reduction in SVHRP-fed worms (Figure 3D). These results
would suggest that the paralysis suppression by SVHRP might
be mediated by inhibiting Aβ oligomerization and amyloid
deposition, which is directly associated with Aβ-toxicity in
the C. elegans transgenic model. Recently, some studies have
found Aβ has some physiological roles on synaptic plasticity
and memory (Morley et al., 2010; Puzzo et al., 2011). Since
the absence of endogenous Aβ production in the wild type
worms, more research is needed to investigate the impact of
SVHRP on the physiological production of Aβ and synaptic
plasticity.
According to the “amyloid cascade” hypothesis, oxidative
stress induced by Aβ may be involved in the pathogenesis
of AD (Butterfield, 1997). In this study, we report SVHRP
reduced superoxide production in the transgenic C. elegans
strains CL4176. In C. elegans, ROS production is a typical
outcome of amyloid deposition and the effect of SVHRP on
ROS production may be a consequence of amyloid reduction.
But we can’t exclude the possibility that SVHRP has direct
scavenging effects on ROS, since the antioxidant properties
of SVHRP have also been observed in the experimental
model where increased oxidative stress was not induced by
Aβ (Yin et al., 2014). A large number of studies in AD
mouse model have suggested the antioxidant-based therapies
as a potential avenue to mitigate AD (Moreira et al.,
2006; Dumont et al., 2009) and the antioxidant activity of
SVHRP might contribute to protecting against the Aβ-induced
damage.
The transgenic C. elegans strains, CL4176 and CL2006, which
express the human Aβ1−42 in muscle tissues, reflect the toxicity
of Aβ oligomers to muscle cells. However, in AD, Aβ is
primarily toxic to neurons. We chose another transgenic strain,
CL2355, expressing Aβ in neuronal cells to investigate whether
SVHRP could protect neuron against Aβ-induced toxicity in
C. elegans. These nematodes exhibit defects in chemotaxis
behavior due to Aβ induced toxicity (Wu et al., 2006). By
using the transgenic strain CL2355, we found SVHRP could
also protect neuronal cells against amyloid toxicity in vivo
results in a strong protection against the pathological phenotype
(Figure 5B). Our previous experiments have demonstrated that
SVHRP had neurotrophic and neuroprotective effects (Wang
et al., 2014; Yin et al., 2014). SVHRP could enhance neurogenesis
and stimulate neural maturation by up-regulating BDNF (Wang
et al., 2014). However, the neurotrophic effects of SVHRP by
up-regulating BDNF may not contribute to rescuing Aβ toxicity
induced defects in chemotaxis behavior, since C. elegans really
do not have BDNF per se. Further research using higher order
experimental models is needed to clarify the exact molecular
and cellular mechanisms underlying SVHRP neuroprotective
activity.
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In summary, in this study, we found that SVHRP-
polypeptide extract from scorpion venoms alleviated Aβ-induced
paralysis and chemotaxis dysfunction in the transgenic
C. elegans expressing Aβ. SVHRP also modulated Aβ
oligomers and attenuated levels of ROS in the transgenic
C. elegans. Though the mechanisms behind the protective
effect of SVHRP in C. elegans remain unclear, our results
suggest SVHRP is worthy of further studies with murine
models in order to validate the effectiveness of this
peptide.
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